Using ctDNA to Guide Clinical Decision Making in Phase I Oncology Trials
Time: 2:30 pm
day: Day Two
Details:
- ctDNA can be more useful than tumor tissue in identification or screening patients
- ctDNA can be a PD biomarker as well early indicator of clinical efficacy
- Longitudinal monitoring emerging tumor gene alterations in ctDNA can help understand resistance mechanisms and guide patient management
